To mitigate the risk of tumor recurrence, the goal is to achieve a negative margin status, a term used to define a tumor-free surgical margin. įor the past several decades, surgery has been the first-line treatment for STS. This survival discrepancy between adults and children is often attributed to reduced radio- or chemosensitivity with increasing age. For example, adult patients with rhabdomyosarcoma (derived from skeletal muscle cells), synovial sarcomas (with partial epithelial differentiation), and fibrosarcoma (originating from tendon and fascia), have substantially lower five-year overall survival rates and higher risk of recurrence or metastasis than pediatric patients. Many STS subtypes are highly malignant and aggressive, more so in adults than in children. Due to its rarity and heterogenicity, it is likely that STS incidences are underestimated and initially misdiagnosed which could adversely affect patient outcomes. Soft tissue sarcomas (STS), one of the two major subclasses of sarcoma, arise from diverse connective tissue and are more frequently diagnosed than bone sarcomas, which arise from bone or cartilage. Sarcomas are also extremely heterogeneous with over 50 different histological subtypes, many of which can occur at any age or anatomical location. Accounting for 20% and <1% of all pediatric and adult solid tumors, respectively, sarcomas are exceedingly rare. Sarcoma is one of the major types of cancer and refers to tumors derived from mesenchymal or neural crest cells. CHCP treatment reduced the viability of four different STS cell lines (i.e., fibrosarcoma, synovial sarcoma, rhabdomyosarcoma, and liposarcoma) in a dose-dependent manner by inhibiting proliferation, disrupting cell cycle, and inducing apoptosis-like cell death. In this study, the authors evaluate the efficacy of CHCP across multiple STS cell lines. This preliminary study was conducted in vitro prior to in vivo testing in a humanitarian compassionate use case study and an FDA-approved phase 1 clinical trial (IDE G190165). Canady Cold Helios Plasma (CHCP) is a device that sprays CAP along the surgical margins to eradicate residual cancer cells after tumor resection. Cold atmospheric plasma (CAP) is a novel technology that has demonstrated immense cancer therapeutic potential. Additionally, current polychemotherapeutic regimens are highly toxic with no rational survival benefit. Complete removal of STS by surgery is challenging due to the anatomical location of the tumor, which results in tumor recurrence. Soft tissue sarcomas (STS) are a rare and highly heterogeneous group of solid tumors, originating from various types of connective tissue.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |